Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines. Nishi T, Morita A, Hara N, Makimoto G, et al. Lung Cancer 2025;201:108415.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nishi T, Morita A, Hara N, Makimoto G, et al. Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines. Lung Cancer 2025;201:108415.
PMID: 39922174